For example, by functionalizing the nanoparticle surface with tumor-specific ligands or antibodies, the nanoparticles can selectively bind to receptors overexpressed on HCC cells, such as glypican-3 (GPC3) or transferrin receptors 20, 21. This evidence concerns the gene TFRC and neoplasm.